BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 28477890)

  • 1. Epstein-Barr Virus-associated Lymphoproliferative Disorders in the Skin.
    Goodlad JR
    Surg Pathol Clin; 2017 Jun; 10(2):429-453. PubMed ID: 28477890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-Barr virus-associated T- and NK-cell lymphoproliferative diseases: an update and diagnostic approach.
    Hue SS; Oon ML; Wang S; Tan SY; Ng SB
    Pathology; 2020 Jan; 52(1):111-127. PubMed ID: 31767131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The understanding of Epstein-Barr virus associated lymphoproliferative disorder].
    Zhou XG; Zhang YL; Xie JL; Huang YH; Zheng YY; Li WS; Chen H; Liu F; Pan HX; Wei P; Wang Z; Hu YC; Yang KY; Xiao HL; Wu MJ; Yin WH; Mei KY; Chen G; Yan XC; Meng G; Xu G; Li J; Tian SF; Zhu J; Song YQ; Zhang WJ
    Zhonghua Bing Li Xue Za Zhi; 2016 Dec; 45(12):817-821. PubMed ID: 28056294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on viral-induced cutaneous lymphoproliferative disorders. CME Part I.
    Plaza JA; Gru AA; Sangueza OP; Lourenco SV; Puccio FB; Sanches JA; Miyashiro D; Toussaint S; Sangueza MJ
    J Am Acad Dermatol; 2023 May; 88(5):965-980. PubMed ID: 36041557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein - Barr virus positive T and NK-cell lymphoproliferations: Morphological features and differential diagnosis.
    Montes-Mojarro IA; Kim WY; Fend F; Quintanilla-Martinez L
    Semin Diagn Pathol; 2020 Jan; 37(1):32-46. PubMed ID: 31889602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus-associated lymphoproliferative disorders.
    Rezk SA; Weiss LM
    Hum Pathol; 2007 Sep; 38(9):1293-304. PubMed ID: 17707260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders.
    Quintanilla-Martinez L; Swerdlow SH; Tousseyn T; Barrionuevo C; Nakamura S; Jaffe ES
    Virchows Arch; 2023 Jan; 482(1):227-244. PubMed ID: 36216980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus: dermatologic associations and implications: part II. Associated lymphoproliferative disorders and solid tumors.
    Eminger LA; Hall LD; Hesterman KS; Heymann WR
    J Am Acad Dermatol; 2015 Jan; 72(1):21-34; quiz 35-6. PubMed ID: 25497918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphomatoid granulomatosis and other Epstein-Barr virus associated lymphoproliferative processes.
    Dunleavy K; Roschewski M; Wilson WH
    Curr Hematol Malig Rep; 2012 Sep; 7(3):208-15. PubMed ID: 22814713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological categorization of hydroa vacciniforme-like lymphoproliferative disorder: an analysis of prognostic implications and treatment based on 19 cases.
    Guo N; Chen Y; Wang Y; Huang Y; Feng Y; Li M; Rao H
    Diagn Pathol; 2019 Jul; 14(1):82. PubMed ID: 31315684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric oral Epstein-Barr virus associated self-remitting CD30+ lymphoproliferative disorder: A distinct entity.
    Schwartz Z; Bowe RB; Coleman M; Magro CM
    Ann Diagn Pathol; 2018 Dec; 37():57-61. PubMed ID: 30292067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Common cytological and cytogenetic features of Epstein-Barr virus (EBV)-positive natural killer (NK) cells and cell lines derived from patients with nasal T/NK-cell lymphomas, chronic active EBV infection and hydroa vacciniforme-like eruptions.
    Zhang Y; Nagata H; Ikeuchi T; Mukai H; Oyoshi MK; Demachi A; Morio T; Wakiguchi H; Kimura N; Shimizu N; Yamamoto K
    Br J Haematol; 2003 Jun; 121(5):805-14. PubMed ID: 12780797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus-positive cytotoxic T-cell lymphoma followed by chronic active Epstein-Barr virus infection-associated T/NK-cell lymphoproliferative disorder: a case report.
    Kato S; Miyata T; Takata K; Shimada S; Ito Y; Tomita A; Elsayed AA; Takahashi E; Asano N; Kinoshita T; Kimura H; Nakamura S
    Hum Pathol; 2013 Dec; 44(12):2849-52. PubMed ID: 24012167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr virus NK and T cell lymphoproliferative disease: report of a 2018 international meeting.
    Cohen JI; Iwatsuki K; Ko YH; Kimura H; Manoli I; Ohshima K; Pittaluga S; Quintanilla-Martinez L; Jaffe ES
    Leuk Lymphoma; 2020 Apr; 61(4):808-819. PubMed ID: 31833428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical hydroa vacciniforme-like epstein-barr virus associated T/NK-cell lymphoproliferative disorder.
    Lee HY; Baek JO; Lee JR; Park SH; Jeon IS; Roh JY
    Am J Dermatopathol; 2012 Dec; 34(8):e119-24. PubMed ID: 23169419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disorders.
    Park S; Ko YH
    J Dermatol; 2014 Jan; 41(1):29-39. PubMed ID: 24438142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous EBV-related lymphoproliferative disorders.
    Gru AA; Jaffe ES
    Semin Diagn Pathol; 2017 Jan; 34(1):60-75. PubMed ID: 27988064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of skin blister fluids from children with Epstein-Barr virus-associated lymphoproliferative disease.
    Wada T; Toma T; Miyazawa H; Koizumi E; Shirahashi T; Matsuda Y; Yachie A
    J Dermatol; 2018 Apr; 45(4):444-449. PubMed ID: 29352500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A unique presentation of an Epstein-Barr virus-associated natural killer/T-cell lymphoproliferative disorder in a white male adolescent.
    Summers E; Samadashwily G; Florell SR
    Arch Dermatol; 2011 Feb; 147(2):216-20. PubMed ID: 21339449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroa vacciniforme-like Epstein-Barr virus-associated monoclonal T-lymphoproliferative disorder in a child.
    Wu YH; Chen HC; Hsiao PF; Tu MI; Lin YC; Wang TY
    Int J Dermatol; 2007 Oct; 46(10):1081-6. PubMed ID: 17910721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.